What is Riboscience?
Riboscience operates at the intersection of precision medicine and molecular biology, utilizing a proprietary structure-guided design platform to engineer novel RNA-based drug candidates. The company distinguishes itself by addressing previously untreatable disease states, moving beyond traditional small-molecule limitations. Its current flagship asset, an ENPP1 inhibitor, is currently undergoing Phase 2 clinical trials, underscoring the firm's transition from early-stage research to advanced clinical validation. By focusing on first-in-class and best-in-class therapeutic modalities, Riboscience is establishing a robust market position within the competitive biotechnology landscape, aiming to redefine standards of care for patients with limited treatment options.
How much funding has Riboscience raised?
Riboscience has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Riboscience
PPP
Public-Private Partnership
What's next for Riboscience?
With the recent capital infusion, Riboscience is poised to scale its operational capacity and advance its lead clinical assets through the regulatory pipeline. The strategic focus will likely center on the successful completion of Phase 2 trials for its ENPP1 inhibitor, while simultaneously expanding its drug discovery platform to address a broader spectrum of viral and oncological targets. As the company matures, the emphasis will shift toward potential commercialization partnerships and the optimization of its manufacturing processes to ensure scalability. This late-stage funding environment provides the necessary runway to solidify the company's intellectual property portfolio and enhance its competitive moat in the rapidly evolving RNA therapeutics sector.
See full Riboscience company page
